AstraZeneca ( (GB:AZN) ) has issued an update.
AstraZeneca’s Imfinzi has been approved by the European Union as the first immunotherapy for limited-stage small cell lung cancer (LS-SCLC), following the successful ADRIATIC Phase III trial. This approval marks a significant advancement in treatment options, as Imfinzi demonstrated a 27% reduction in the risk of death compared to placebo, offering a new benchmark for LS-SCLC care and potentially transforming outcomes for patients in Europe.
More about AstraZeneca
AstraZeneca is a leading pharmaceutical company specializing in oncology, immuno-oncology, and lung cancer treatments. The company is known for its innovative approaches to cancer care, including the development of immunotherapies and a diverse portfolio of medicines aimed at improving outcomes for patients with various types of cancer.
YTD Price Performance: 16.25%
Average Trading Volume: 2,817,366
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £186B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.